Table 4 Best response to treatment, and TTP on first line with cetuximab according to EGFR and PTEN status assessed by IHC and FISH
From: Potential value of PTEN in predicting cetuximab response in colorectal cancer: An exploratory study
Number of patients | Response Rate | TTP on first line with cetuximab | |
|---|---|---|---|
(N = 72) | N (%) | (months) | |
IHC | |||
EGFR | |||
Negative | 33 | 14 (42%) | 6.85 |
Positive | 38 | 10 (26%) | 5.93 |
NE | 1 | ||
P-value | 0.60 | ||
PTEN | |||
No loss | 62 | 19 (31%) | 6.39 |
Loss | 10 | 5 (50%) | 9.44 |
P-value | 0.54 | ||
FISH | |||
EGFR | |||
Normal | 56 | 20 (36%) | 6.85 |
Gain | 5 | 1 (20%) | 8.72 |
Deletion | 5 | 1 (20%) | 6.39 |
NE | 6 | ||
P-value | 0.18 | ||
PTEN | |||
Normal | 43 | 18 (42%) | 7.41 |
Gain | - | - | - |
Deletion | 23 | 3 (13%) | 5.28 |
NE | 6 | ||
P-value | 0.042 |